A new vaccine, ELI-002 from Elicio Therapeutics, is generating excitement in early trials for KRAS-driven pancreatic and colorectal cancers. In the phase 1 AMPLIFY-201 study, more than 80% of patients developed strong T-cell responses — a signal linked to longer relapse-free and overall survival. Lead investigator Zev Wainberg, MD (UCLA) reported tumor biomarker clearance in some patients, with no severe side effects.
Experts like Magnus Dillon, PhD and Richard Sullivan, PhD welcomed the findings but urged caution — calling the data promising yet far from proven efficacy. Larger trials will decide whether this vaccine can truly change outcomes for patients facing two of the toughest cancers.